Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
Public ClinicalTrials.gov record NCT04318548. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age
Study identification
- NCT ID
- NCT04318548
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 945 participants
Conditions and interventions
Conditions
Interventions
- Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ) Combination Product
- Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid) Biological
- Placebo Combination Product
Combination Product · Biological
Eligibility (public fields only)
- Age range
- 16 Years to 18 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 24, 2020
- Primary completion
- Nov 20, 2023
- Completion
- Nov 20, 2023
- Last update posted
- Mar 3, 2025
2020 – 2023
United States locations
- U.S. sites
- 49
- U.S. states
- 17
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Phoenix | Arizona | 85238 | — |
| GSK Investigational Site | Bell Gardens | California | 90201 | — |
| GSK Investigational Site | Los Angeles | California | 90027 | — |
| GSK Investigational Site | Oakland | California | 94611 | — |
| GSK Investigational Site | Roseville | California | 95661 | — |
| GSK Investigational Site | Sacramento | California | 95815 | — |
| GSK Investigational Site | San Jose | California | 95119 | — |
| GSK Investigational Site | Santa Clara | California | 95051 | — |
| GSK Investigational Site | Walnut Creek | California | 94596 | — |
| GSK Investigational Site | Wellington | Florida | 33470 | — |
| GSK Investigational Site | Boise | Idaho | 83702 | — |
| GSK Investigational Site | Nampa | Idaho | 83686 | — |
| GSK Investigational Site | Nampa | Idaho | 83687 | — |
| GSK Investigational Site | Evansville | Indiana | 47715 | — |
| GSK Investigational Site | Bardstown | Kentucky | 40004 | — |
| GSK Investigational Site | Louisville | Kentucky | 40291 | — |
| GSK Investigational Site | Lafayette | Louisiana | 70508 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68504 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68505 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68516 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68526 | — |
| GSK Investigational Site | Cortland | New York | 13045 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28226 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| GSK Investigational Site | Corvallis | Oregon | 97330 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16508 | — |
| GSK Investigational Site | Hermitage | Pennsylvania | 16148 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15025 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15217 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15234 | — |
| GSK Investigational Site | Charleston | South Carolina | 29414 | — |
| GSK Investigational Site | Sioux Falls | South Dakota | 57108 | — |
| GSK Investigational Site | Austin | Texas | 75010 | — |
| GSK Investigational Site | Austin | Texas | 78613 | — |
| GSK Investigational Site | Austin | Texas | 78726 | — |
| GSK Investigational Site | Dallas | Texas | 75230-2571 | — |
| GSK Investigational Site | Dallas | Texas | 75251 | — |
| GSK Investigational Site | Houston | Texas | 77584 | — |
| GSK Investigational Site | Plano | Texas | 75024 | — |
| GSK Investigational Site | Plano | Texas | 75093 | — |
| GSK Investigational Site | Victoria | Texas | 77901 | — |
| GSK Investigational Site | Waxahachie | Texas | 75165 | — |
| GSK Investigational Site | Orem | Utah | 84057 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84107 | — |
| GSK Investigational Site | South Jordan | Utah | 84095 | — |
| GSK Investigational Site | Syracuse | Utah | 84075 | — |
| GSK Investigational Site | Falls Church | Virginia | 22044 | — |
| GSK Investigational Site | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04318548, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04318548 live on ClinicalTrials.gov.